Three-dimensional modeling of ovarian cancer

Advanced Drug Delivery Reviews

Volumn 79, Issue , 2014, Pages 184-192

  White, Erin A ^a   Kenny, Hilary A ^a   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

3D models; Breast cancer; Fallopian tube; Melanoma; Metastasis; Ovarian cancer; Tumor microenvironment

Indexed keywords

3D MODELING; DISEASES; PATHOLOGY; TUMORS;

BREAST CANCER; FALLOPIAN TUBE; MELANOMA; METASTASIS; OVARIAN CANCERS; TUMOR MICROENVIRONMENT;

THREE DIMENSIONAL COMPUTER GRAPHICS;

ALGINIC ACID; EARLY GROWTH RESPONSE FACTOR 1; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

BASEMENT MEMBRANE; BIOENGINEERING; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER MODEL; CELL FUNCTION; CELL INVASION; CELL ISOLATION; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; CYTOLOGY; ENDOMETRIOID CARCINOMA; EPITHELIAL CANCER CELL LINE; EPITHELIAL MESENCHYMAL TRANSITION; EX VIVO STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HYDROGEL; IMMUNOFLUORESCENCE; MELANOMA; MESOTHELIUM CELL; METASTASIS; MICROFLUIDICS; MONOLAYER CULTURE; OVARIAN CANCER CELL LINE; OVARY CANCER; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SPHEROID CELL; THREE DIMENSIONAL CANCER CELL CULTURE; TISSUE CULTURE; TUMOR MICROENVIRONMENT; UTERINE TUBE; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE TECHNIQUE; FEMALE; NEOPLASM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL CULTURE TECHNIQUES; FEMALE; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84919474192     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.07.003     Document Type: Review

References (89)

1. Landen C.N., Birrer M.J., Sood A.K. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 2008, 26:995-1005.
2. Bowtell D.D. The genesis and evolution of high-grade serous ovarian cancer. Nat. Rev. Cancer 2010, 10:803-808.
3. Karst A.M., Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J. Oncol. 2013, 2010:1-13.
4. Lengyel E. Ovarian cancer development and metastasis. Am. J. Pathol. 2010, 177:1053-1064.
5. Dubeau L., Drapkin R. Coming into focus: the nonovarian origins of ovarian cancer. Ann. Oncol. 2013, 24.
6. Levanon K., Crum C.P., Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 2008, 26:5284-5293.
7. Nik N.N., Vang R., Shih Ie M., Kurman R.J. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu. Rev. Pathol. 2014, 9:27-45.
8. Tavassoli F.A., Devilee P. Tumors of the ovary and peritoneum. Tumors of the Breast and Female Genital Organs 2003, 113-203. IARC Press, Lyon. P. Kleihues, L. Sobin (Eds.).
9. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 2009, 9:415-428.
10. Vaughan S., Coward J.I., Bast R.C., Berchuck A., Berek J.S., Brenton J.D., Coukos G., Crum C.P., Drapkin R., Etemadmoghadam D., Friedlander M., Gabra H., Kaye S.B., Lord C.J., Lengyel E., Levine D.A., McNeish I.A., Menon U., Mills G.B., Nephew K.P., Oza A., Sood A.K., Stronach E.A., Walczak H., Balkwill F.R. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11:719-725.
11. Berns E.M.J.J., Bowtell D.D. The changing view of high-grade serous ovarian cancer. Cancer Res. 2012, 72:2701-2704.
12. Siegal R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2013, 63:11-30.
13. Erickson B.K., Conner M.G., Landen C.N. The role of the fallopian tube in the origin of ovarian cancer. Am. J. Obstet. Gynecol. 2013, 1-6.
14. Kurman R.J., Shih I.M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 2010, 34:433-443.
15. Piek J.M., van Diest P.J., Zweemer R.P., Jansen J.W., Poort-Keesom R.J., Menko F.H., Gille J.J., Jongsma A.P., Pals G., Kenemans P., Verheijen R.H. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 2001, 195:451-456.
16. Kindelberger D.W., Lee Y., Miron A., Hirsch M.S., Feltmate C., Medeiros F., Callahan M.J., Garner E.O., Gordon R.W., Birch C., Berkowitz R.S., Muto M.G., Crum C.P. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007, 31:161-169.
17. Colgan T.J., Murphy J., Cole D., Narod S.A., Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 2001, 25:1283-1289.
18. Medeiros F., Muto M.G., Lee Y., Elvin J., Callahan M.J., Felmate C., Garber J., Cramer D., Crum C.P. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 2006, 30:230-236.
19. Lee Y., Miron A., Drapkin R., Nucci M.R., Medeiros F., Saleemuddin A., Garber J., Birch C., Mou H., Gordon R.W., Cramer D.W., McKeon F.D., Crum C.P. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 2007, 211:26-35.
20. Kuhn E., Kurman R.J., Vang R., Sehdev A.S., Han G., Soslow R., Want T.L., Shih L.M. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J. Pathol. 2012, 226:421-426.
21. Chen E.Y., Mehra K., Mehrad M., Ning G., Miron A., Mutter G.L., Monte N., Quade B., McKeon F.D., Yassin Y., Crum C.P. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the fallopian tube. J. Pathol. 2010, 222:110-116.
22. Perets R., Wyant G.A., Muto K.W., Bijron J.G., Poole B.B., Chin K.T., Chen J.Y.H., Ohman A.W., Stekpule C.D., Kwak S., Karst A.M., Hirsch M.S., Setlur S.R., Crum C.P., Dinulescu D.M., Drapkin R. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca; Tp53; Pten models. Cancer Cell 2013, 24:751-765.
23. Sherman-Baust C.A., Kuhn E., Valle B.L., Shih I.M., Kurman R.J., Wang T.L., Amano T., Ko M.S., Miyoshi I., Araki Y., Lehrmann E., Zhang Y., Becker K.G., Morin P.J. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J. Pathol. 2014, 233:228-237.
24. Lengyel E., Burdette J.E., Kenny H.A., Matei D., Pilrose J., Haluska P., Nephew K.P., Hales D.B., Stack M.S. Epithelial ovarian cancer experimental models. Oncogene 2014, 33:3619-3633.
25. Karst A.M., Drapkin R. The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Med. Rep. 2011, 3:1-7.
26. The Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
27. Gorringe K.L., George J., Anglesio M.S., Ramakrishna M., Etemadmoghadam D., Cowin P., Sridhar A., Williams L.H., Boyle S.E., Yanaihara N., Okamoto A., Urashima M., Australian Ovarian Cancer Study, Smyth G.K., Campbell I.G., Bowtell D.D. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One 2010, 5.
28. Kenny H.A., Nieman K.M., Mitra A.K., Lengyel E. The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov. 2011, 1:100-102.
29. Fleming G.F., Seidman J.D., Lengyel E. Epithelial ovarian cancer. Principles and Practice of Gynecologic Oncology 2013, 757-848. Lippincott Williams & Wilkins, Philadelphia. R.R. Barakat, A. Berchuck, M. Markmann, M.E. Randall (Eds.).
30. Debnath J., Brugge J.S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 2005, 5:675-688.
31. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
32. Bissell M.J., Radisky D. Putting tumours in context. Nat. Rev. Cancer 2001, 1:46-54.
33. Berking C., Herlyn M. Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology. Histol. Histopathol. 2001, 16:669-674.
34. Weigelt B., Ghajar C.M., Bissell M.J. The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv. Drug Deliv. Rev. 2014, 69-70:42-51.
35. Weaver V.M., Howlett A.R., Langton-Webster B., Petersen O.W., Bissell M.J. The development of a functionally relevant cell culture model of progressive human breast cancer. Semin. Cancer Biol. 1995, 6:175-184.
36. Weaver V.M., Fischer A.H., Peterson O.W., Bissell M.J. The importance of the microenvironment in breast cancer progression: recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay. Biochem. Cell Biol. 1996, 74:833-851.
37. Schmeichel K.L., Bissell M.J. Modeling tissue-specific signaling and organ function in three dimensions. J. Cell Sci. 2003, 116:2377-2388.
38. Lee G.Y., Kenny P.A., Lee E.H., Bissell M.J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 2007, 4:359-365.
39. Weaver V.M., Lelièvre S., Lakins J., Chrenek M.A., Jones C.R., Giancotti F.G., Werb Z., Bissell M.J. β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002, 2:205-216.
40. Briand P., Nielsen K.V., Madsen M.W., Petersen O.W. Trisomy 7p and malignant transformation of human breast epithelial cells following epidermal growth factor withdrawal. Cancer Res. 1996, 56:2039-2044.
41. Peterson O.W., Ronnov-Jessen L., Bissell M.J. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant breast epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:9064-9068.
42. Leung C.T., Brugge J.S. Outgrowth of single oncogene-expressing cells from suppressive epithelial environments. Nature 2012, 482:410-413.
43. Smalley K.S., Lioni M., Herlyn M. Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell. Dev. Biol. Anim. 2006, 42:242-247.
44. Hsu M., Shih D., Meier F.E., van Belle P.A., Hse J., Elder D.E., Buck C., Herlyn M. Adenoviral gene transfer of β3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am. J. Pathol. 1998, 153:1435-1441.
45. Meier F.E., Nesland M., Hsu M., Martin B., van Belle P.A., Elder D.E., Schaumburg-Lever G., Garbe C., Walz T.M., Donatien P., Crombleholme T., Herlyn M. Human melanoma progression in skin reconstructs. Am. J. Pathol. 2000, 156:193-200.
46. Li L., Fukunaga-Kalabis M., Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J. Vis. Exp. 2011, 54:1-5.
47. Yu H., McDaid R., Lee J., Possik P., Li L., Kumar S.M., Elder D.E., Van Belle P., Gimotty P., Guerra M., Hammond R., Nathanson K.L., Dalla Palma M., Herlyn M., Xu X. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am. J. Pathol. 2009, 174:2367-2377.
48. Lee J.T., Li L., Brafford P.A., van den Eijnden M., Halloran M.B., Sproesser K., Haass N.K., Smalley K.S., Tsai J., Bollag G., Herlyn M. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res. 2010, 23:820-827.
49. Stewart C., Behringer R.R. Mouse oviduct development. Results Probl. Cell Differ. 2012, 55:247-262.
50. Levanon K., Ng V., Piao H., Zhang Y., Chang M.C., Roh M.H., Kindelberger D.W., Hirsch M.S., Crum C.P., Marto J.A., Drapkin R. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2009, 1-11.
51. Karst A.M., Levanon K., Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:7547-7552.
52. Karst A.M., Drapkin R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat. Protoc. 2012, 7:1755-1764.
53. Lawrenson K., Notaridou M., Lee N., Benjamin E., Jacobs I.J., Jones C., Gayther S.A. In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. BMC Cell Biol. 2013, 27:1-15.
54. Lawrenson K., Sproul D., Grun B., Notaridou M., Benjamin E., Jacobs I.J. Modelling genetic and clinical heterogeneity in epithelial ovarian cancers. Carcinogenesis 2011, 32:1540-1549.
55. Lee J.M., Mhawech-Fauceglia P., Lee N., Parsanian L.C., Lin Y.G., Gayther S.A., Lawrenson K. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab. Invest. 2013, 93:528-542.
56. King S.M., Quartuccio S., Hillard T.S., Inoue K., Burdette J.E. Alginate hydrogels for three-dimensional organ culture of ovaries and oviducts. J. Vis. Exp. 2011, 52:1-6.
57. Jackson K.S., Inoue K., Davis D.A., Hillard T.S., Burdette J.E. Three-dimensional ovarian organ culture as a tool to study normal ovarian surface epithelial wound repair. Endocrinology 2009, 150:3921-3926.
58. King S.M., Quartuccio S.M., Vanderhyden B.C., Burdette J.E. Early transformative changes in normal ovarian surface epithelium induced by oxidative stress require Akt upregulation, DNA damage and epithelial-stromal interaction. Carcinogenesis 2013, 34:1125-1133.
59. King S.M., Hilliard T.S., Wu L.Y., Jaffe R.C., Fazleabas A.T., Burdette J.E. The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer. Endocr. Relat. Cancer 2011, 18:627-642.
60. Barbolina M.V., Adley B.P., Ariztia E.V., Liu Y., Stack M.S. Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J. Biol. Chem. 2007, 282:4924-4931.
61. Barbolina M.V., Moss N.M., Westfall S.D., Liu Y., Burkhalter R.J., Marga F., Forgacs G., Hudson L.G., Stack M.S. Microenvironmental regulation of ovarian cancer metastasis. Cancer Treat. Res. 2009, 149:319-334.
62. Mitra A.K., Sawada K., Tiwari P., Mui K., Gwin K., Lengyel E. Ligand-independent activation of c-Met by fibronectin and α 5 β 1-integrin regulates ovarian cancer invasion and metastasis. Oncogene 2011, 30:1566-1576.
63. Loessner D., Stok K.S., Lutolf M.P., Hutmacher D.W., Clements J.A., Rizzi S.C. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31:8494-8506.
64. Loessner D., Rizzi S.C., Stok K.S., Fuehrmann T., Hollier B., Magdolen V., Hutmacher D.W., Clements J.A. A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread. Biomaterials 2013, 34:7389-7400.
65. Wilkoxz S., Ireland G., Khwaja N., Walker M., Butt R., Giorgio-Miller A., Herrick S. A comparative study of the structure of human and murine greater omentum. Anat. Embryol. 2005, 209:251-261.
66. Liebermann-Meffert D. The greater omentum, anatomy, embryology, and surgical applications. Surg. Clin. N. Am. 2000, 80:275-293.
67. Kenny H.A., Dogan S., Zillhardt M., Mitra A.B., Yamada S.D., Krausz T., Lengyel E. Organotypic models of metastasis: a three dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat. Res. 2009, 149:335-351.
68. Witz C.A., Montoya-Rodriguez I.A., Cho S., Centonze V.E., Bonewald L., Schenken R.S. Composition of the extracellular matrix of the peritoneum. J. Soc. Gynecol. Investig. 2001, 8:299-304.
69. Kenny H.A., Krausz T., Yamada S.D., Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells. Int. J. Cancer 2007, 121:1463-1472.
70. Kenny H.A., Leonhardt P., Ladanyi A., Yamada S.D., Montag A.G., Im H.K., Jagadeeswaran S., Shaw D.E., Mazar A.P., Lengyel E. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin. Cancer Res. 2011, 17:459-471.
71. Kenny H.A., Kaur S., Coussens L.M., Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J. Clin. Invest. 2008, 118:1367-1379.
72. Lee K.Y., Seow E., Zhang Y., Lim Y.C. Targeting CCL21-folic acid-upconversion nanoparticles conjugates to folate receptor-α expressing tumor cells in an endothelial-tumor cell bilayer model. Biomaterials 2013, 34:4860-4871.
73. Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M., Romero I.L., Carey M.S., Mills G.B., Hotamisligil G.S., Yamada S.D., Peter M.E., Gwin K., Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 2011, 17:1498-1503.
74. Nieman K.M., Romero I.L., Van Houten B., Lengyel E. Adipocyte tissue and adipocytes support tumorigenesis and metastasis. Biochim. Biophys. Acta 2013, 1831:1533-1541.
75. Khan S.M., Funk H.M., Thiolloy S., Lotan T.L., Hickson J.A., Prins G., Drew A.F., Rinker-Schaeffer C.W. In vitro metastatic colonization of human ovarian cancer cells to the omentum. Clin. Exp. Metastasis 2010, 27:185-196.
76. Clark R., Krishnan V., Schoof M., Rodriguez I., Theriault B., Chekmareva M., Rinker-Schaeffer C. Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models. Am. J. Pathol. 2013, 183:576-591.
77. Allen H.J., Porter C., Gamarra M., Piver M.S., Johnson E.A. Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions. Exp. Cell Biol. 1987, 55:194-208.
78. Burleson K.M., Hansen L.K., Skubitz A.P. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin. Exp. Metastasis 2004, 21:685-697.
79. Burleson K.M., Casey R.C., Skubitz K.M., Pambuccian S.E., Oegema T.R., Skubitz A.P. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol. 2004, 93:170-181.
80. Burleson K.M., Boente M.P., Pambuccian S.E., Skubitz A.P. Dissaggregation and invasion of ovarian carcinoma ascites spheroids. J. Transl. Med. 2006, 24:4-6.
81. Iwanicki M., Davidowitz R.A., Ng M.R., Besser A., Muranen T., Merritt M., Danuser G., Ince T.A., Brugge J.S. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011, 1:144-157.
82. Davidowitz R.A., Selfors L.M., Iwanicki M.P., Elias K.M., Karst A., Piao H., Ince T.A., Drage M.G., Dering J., Konecny G.E., Matulonis U., Mills G.B., Slamon D.J., Drapkin R., Brugge J.S. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J. Clin. Invest. 2014, 124:2611-2625.
83. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., Gao S., Mills G.B., Brugge J.S. Inhibition of P13K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
84. Rizvi I., Gurkan U.A., Tasoglu S., Alagic N., Celli J.P., Mensah L.B., Mai Z., Demirci U., Hasan T. Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules. Proc. Natl. Acad. Sci. U. S. A. 2013, E1974-E1983.
85. Butler J.M., Kobayashi H., Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer 2010, 10:138-146.
86. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
87. Schmitt J., Matei D. Targeting angiogenesis in ovarian cancer. Cancer Treat. Rev. 2012, 38:272-283.
88. Elinav E., Nowarski R., Thaiss C.A., Hu B., Chengcheng J., Flavell R.A. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 2013, 13:759-771.
89. Robins H.S., Ericson N.G., Guenthoer J., O'Briant K.C., Tewari M., Drescher C.W., Bielas J.H. Digital genomic quantification of tumor-infiltrating lymphocytes. Sci. Transl. Med. 2014, 5:1-7.